Skip Nav Destination
Issues
1 June 2009
-
Cover Image
Cover Image
The cover features a 3-dimensional graph of the distribution of the sizes of particles of polyphenon E (Poly E), a mixture of epigallocatechin 3-gallate (EGCG) and at least four other catechins found in green tea. Poly E is the form of green tea commonly used in clinical trials. The particle sizes of Poly E (blue bars) and Poly E stripped of EGCG, or Poly E-light (gray bars), are virtually the same, with a geometric median diameter of 0.13 μm and geometric standard deviation of 1.6 μm. The 0.13 μm diameter of Poly E is many times smaller than any other reported to date, optimizing its aerosolized delivery to and absorption by lung tissue. As reported in this issue of the journal, aerosolized Poly E was more effective than was aerosolized Poly E-light (or EGCG alone) in reducing tumor multiplicity in a model of chemically induced mouse-lung tumorigenesis. The difference in efficacy between Poly E and Poly E-light most likely was due to differences in biological, not physical, properties since the particle sizes of the two compounds were similar. See articles by Fu et al. (beginning on page 531) and Bode and Dong (beginning on page 514) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Historical Perspective
Perspective
Minireview
Commentary
Research Articles
The Effects of Varying Dietary Carbohydrate and Fat Content on Survival in a Murine LNCaP Prostate Cancer Xenograft Model
John C. Mavropoulos; W. Cooper Buschemeyer, III; Alok K. Tewari; Dmitriy Rokhfeld; Michael Pollak; Yunhua Zhao; Phillip G. Febbo; Pinchas Cohen; David Hwang; Gayathri Devi; Wendy Demark-Wahnefried; Eric C. Westman; Bercedis L. Peterson; Salvatore V. Pizzo; Stephen J. Freedland
A Novel Sulindac Derivative That Does Not Inhibit Cyclooxygenases but Potently Inhibits Colon Tumor Cell Growth and Induces Apoptosis with Antitumor Activity
Gary A. Piazza; Adam B. Keeton; Heather N. Tinsley; Bernard D. Gary; Jason D. Whitt; Bini Mathew; Jose Thaiparambil; Lori Coward; Gregory Gorman; Yonghe Li; Brahma Sani; Judith V. Hobrath; Yulia Y. Maxuitenko; Robert C. Reynolds
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.